You have to be extroverted to be a leader. Only if you have employees are you a leader. Either you have it or you don’t. Leaders have a natural gift, you can’t learn it. Those are three typical myths about leaders. In today’s episode, I talk with Gary about these three false beliefs. We point out why …
Statistical innovation is vital in the pharmaceutical industry as it drives evidence-based decisions and brings value to patients. However, it requires a delicate balance between invention and commercialization to achieve success. I, together with Mouna Akacha and Kaspar Rufibach – two leaders of statistical innovation groups in big pharma companies, share their insights on the …
Driving Statistical Innovation – Barriers And Strategies Part 1 Read More »
As a statistician, you’re likely already familiar with SAS and the value it brings to data analysis. But in this ever-evolving world of statistics and data science, relying on your go-to language might not be enough to stay competitive anymore. The open-source language R is gaining traction within the healthcare industry as a powerful tool …
In our world of clinical trials and observational studies, missing data based on drop outs or for others reasons leads to a challenge in understanding how well treatments work. Treatment policy estimands help us to understand efficacy based on early treatment decisions. Various approaches, like reference-based imputation and delta adjustment, exist to speculate what may have …
In any industry, staying competitive and relevant requires a constant focus on innovation and the ability to communicate effectively with customers. In the pharmaceutical industry, this is particularly true as companies race to develop and market new compounds that can improve patient outcomes. In this episode, I share insights into the importance of effective data …
Your compound through the eyes of the competition Read More »
We statisticians play a significant role in the clinical development of pharmaceutical products and medical devices. Many of us focus on designing and analyzing clinical trials to provide evidence for regulatory approval and Health Technology Assessment (HTA). In these set-up, we often talk rather directly to our external clients – regulators and payers (at least …
Beyond Regulatory and HTA Success: Reaching Physicians and Patients Read More »